Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
United Therapeutics Corporation focuses on the strength of a balanced, value-creat...
United Therapeutics Corporation focuses on the ...
Tivity Health, IncÂŽ is a leading provider of fitness and health improvement progr...
Tivity Health, IncÂŽ is a leading provider of f...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
We are a biopharmaceutical company focused on developing our pipeline featuring sp...
We are a biopharmaceutical company focused on d...
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Cara Therapeutics is a clinical-stage biopharma...
Savara is an orphan lung disease company. Savaraâs pipeline comprises Molgradex,...
Savara is an orphan lung disease company. Savar...
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
Autolus is a clinical-stage, biopharmaceutical company, focused on the development...
Autolus is a clinical-stage, biopharmaceutical ...
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative biopharmaceutical company ...
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an in...
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Join the National Investor Network and get the latest information with your interests in mind.